Invalidity dossier
US 9217028
Human cytomegalovirus neutralising antibodies and use thereof
Current assignee: Institute for Research in Biomedicine
Added 9/21/2026, 10:19:26 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 9,217,028 B2
Title: Human cytomegalovirus neutralising antibodies and use thereof
Patent number / application: US 9,217,028 B2; application US 13/618,264; publication US 2013/0171169 A1.
Inventors: Antonio Lanzavecchia and Annalisa Macagno.
Assignee: Institute for Research in Biomedicine (IRB) as original assignee and current assignee listed. The source also records assignments to Humabs, LLC (dated 2012-12-20).
Key dates: Priority date 2007-01-04 (GB 0700133.2); filing date 2012-09-14; granted/publication date 2015-12-22; anticipated expiration 2028-01-03. Legal status shown as "Expired - Fee Related."
Purpose and plain-language scope. The patent concerns potent neutralizing antibodies specific for human cytomegalovirus (hCMV), and immortalized B cells producing such monoclonal antibodies. The disclosed antibodies are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of UL128, UL130 and UL131A. The source describes antibodies 1F11, 2F4, 5A2, 9A11, 7H3, 1006, 5F1 and 6B4, with figures showing precipitation of hCMV protein complexes and FACS recognition of epitopes (the UL130/UL131A combination; gB for 7H3, 1006, 5F1, 6B4). The patent also covers nucleic acids, vectors, cells, epitopes, immunogenic polypeptides, ligands, pharmaceutical compositions, kits for diagnosis of hCMV infection, methods of producing antibodies, and screening methods.
What the excerpt does not establish. It does not provide claim language or claim scope, a full description, or the complete sequence listings; the text is explicitly marked as excerpted, with FIG. 6 cut off. It does not establish that any antibody is clinically effective or approved. It records assignee information as listed, without legal analysis. It does not address litigation, validity, enforceability, inventorship disputes, or prior art.
Source: https://patents.google.com/patent/US9217028/en (fetched 2026-09-21).
Generated 10/1/2026, 10:01:49 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9217028. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.